MEDICUS PHARMA LTD. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
MEDICUS PHARMA LTD. (MDCX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- MEDICUS PHARMA LTD. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.41M, a 1096.98% increase year-over-year.
- MEDICUS PHARMA LTD. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $599.31K, a 433.77% increase year-over-year.
- MEDICUS PHARMA LTD. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $852.76K.
- MEDICUS PHARMA LTD. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $117.45K, a 79.94% decline year-over-year.
- MEDICUS PHARMA LTD. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.51M, a 112.05% increase from fiscal 2024.
- MEDICUS PHARMA LTD. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $713.12K, a 623.35% increase from fiscal 2023.
- MEDICUS PHARMA LTD. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $98.58K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.41M 10-Q · filed 2026-08-12 | $2.01M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $599.31K 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $1.51M 10-K · filed 2026-03-25 | |||
| 2025-09-30 | $852.76K 10-Q · filed 2025-11-14 | $970.21K derived: sum of 2 quarters · filed 2026-08-12 | $1.08M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | $117.45K 10-Q · filed 2026-08-12 | $229.72K derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $112.28K 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $713.12K 10-K · filed 2026-03-25 | |||
| 2024-06-30 | $585.44K 10-Q · filed 2025-11-14 | $621.39K derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $35.95K 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $98.58K 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |